P556: CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB + AZACITIDINE OR PLACEBO + AZACITIDINE

• A. Schuh,
• S. de Botton,
• C. Recher,
• S. Vives Polo,
• E. Zarzycka,
• J. Wang,
• G. Bertani,
• M. Heuser,
• R. Calado,
• S.-P. Yeh,
• J. Hui,
• S. Pandya,
• D. Gianolio,
• C. Chamberlain,
• H. Dohner,
• P. Montesinos

Affiliations

A. Schuh

1 Princess Margaret Cancer Centre, Toronto, Canada

S. de Botton

2 Institut Gustave Roussy, Villejuif

C. Recher

3 Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France

S. Vives Polo

4 Hospital Universitario Germans Trias i Pujol-ICO Badalona, Josep Carreras Research Institute, Badalona, Spain

E. Zarzycka

5 Department of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland

J. Wang

6 Institute of Hematology & Hospital of Blood Disease, Tianjin, China

G. Bertani

7 ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

M. Heuser

8 Hannover Medical School, Hannover, Germany

R. Calado

9 Ribeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil

S.-P. Yeh

10 China Medical University, Taichung, Taiwan

J. Hui

11 Servier Pharmaceuticals LLC, Boston, United States of America

S. Pandya

11 Servier Pharmaceuticals LLC, Boston, United States of America

D. Gianolio

11 Servier Pharmaceuticals LLC, Boston, United States of America

C. Chamberlain

11 Servier Pharmaceuticals LLC, Boston, United States of America

H. Dohner

12 Ulm University Hospital, Ulm, Germany

P. Montesinos

13 Hospital Universitari i Politècnic La Fe, València, Spain